A single dose of the long-acting antibody nirsevimab developed to prevent respiratory syncytial virus infections (The drug has been approved at the European level to protect infants in their first season of exposure to the virus) to infants can halve hospitalizations for bronchiolitis. It is the result of a study involving the Università Cattolica del … Read more
For the first time, U.S. infants saw dramatically fewer RSV hospitalizations thanks to new maternal vaccines and nirsevimab, highlighting the urgent need for early, widespread prevention each season. Study: Interim Evaluation of Respiratory Syncytial Virus Hospitalization Rates Among Infants and Young Children After Introduction of Respiratory Syncytial Virus Prevention Products — United States, October 2024–February … Read more
Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev. 2004;5 SUPPL. A:S119-26. Article PubMed Google Scholar Calvo C, García-García ML, Blanco C, Vázquez MC, Frías ME, Pérez-Breña P, et al. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain. J Clin Virol. 2008;42:268–72. Article … Read more
A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death within one year compared to the general population. The findings underscore the significant, yet often under-recognized, long-term health and economic burden of RSV-ARI in adults, particularly among … Read more
Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively with age and is more likely among people with other health issues and who live in nursing homes, according to a study published in Eurosurveillance. The hospitalization rate varied considerably with age and the presence of risk conditions, with important implications … Read more
During the 2022-23 respiratory virus season, patients infected with SARS-CoV-2 experienced significantly worse disease outcomes when compared with influenza and respiratory syncytial virus (RSV). While these differences were less prominent in the following season, RSV remained significantly mild and COVID-19 had increased long-term mortality outcomes throughout both seasons, according to data published in JAMA Internal … Read more
With the current quad-demic, there are precautions that you can take. For example, after respiratory … [+] syncytial virus (RSV) cases jumped in December 2024, the New York City Health Department suggested that people mask up in crowded indoor places. (Photo by Selcuk Acar/Anadolu via Getty Images) Anadolu via Getty Images This is not how … Read more
Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity -; primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of rejection and others with immune system disorders -; do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same … Read more